Unknown

Dataset Information

0

Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.


ABSTRACT: Resistance to endocrine therapy is a major clinical problem in breast cancer. The role of ERalpha splice variants in endocrine resistance is largely unknown. We observed reduced protein expression of an N-terminally truncated ERalpha46 in endocrine-resistant LCC2, LCC9, and LY2 compared to MCF-7 breast cancer cells. Transfection of LCC9 and LY2 cells with hERalpha46 partially restored growth inhibition by TAM. Overexpression of hERalpha46 in MCF-7 cells reduced estradiol (E(2))-stimulated endogenous pS2, cyclin D1, nuclear respiratory factor-1 (NRF-1), and progesterone receptor transcription. Expression of oncomiR miR-21 was lower in TAM-resistant LCC9 and LY2 cells compared to MCF-7 cells. Transfection with ERalpha46 altered the pharmacology of E(2) regulation of miR-21 expression from inhibition to stimulation, consistent with the hypothesis that hERalpha46 inhibits ERalpha activity. Established miR-21 targets PTEN and PDCD4 were reduced in ERalpha46-transfected, E(2)-treated MCF-7 cells. In conclusion, ERalpha46 appears to enhance endocrine responses by inhibiting selected ERalpha66 responses.

SUBMITTER: Klinge CM 

PROVIDER: S-EPMC2875375 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription.

Klinge Carolyn M CM   Riggs Krista A KA   Wickramasinghe Nalinie S NS   Emberts Celia G CG   McConda David B DB   Barry Parul N PN   Magnusen Joan E JE  

Molecular and cellular endocrinology 20100317 2


Resistance to endocrine therapy is a major clinical problem in breast cancer. The role of ERalpha splice variants in endocrine resistance is largely unknown. We observed reduced protein expression of an N-terminally truncated ERalpha46 in endocrine-resistant LCC2, LCC9, and LY2 compared to MCF-7 breast cancer cells. Transfection of LCC9 and LY2 cells with hERalpha46 partially restored growth inhibition by TAM. Overexpression of hERalpha46 in MCF-7 cells reduced estradiol (E(2))-stimulated endoge  ...[more]

Similar Datasets

| S-EPMC2749102 | biostudies-literature
| S-EPMC4379705 | biostudies-literature
| S-EPMC7924955 | biostudies-literature
| S-EPMC7204353 | biostudies-literature
| S-EPMC5614746 | biostudies-literature
| S-EPMC5986198 | biostudies-literature
| S-EPMC7326724 | biostudies-literature
| S-EPMC5652769 | biostudies-literature
| S-EPMC8514509 | biostudies-literature
| S-EPMC8149656 | biostudies-literature